Public Employees Retirement Association of Colorado Has $138.84 Million Position in Becton Dickinson and Co (NYSE:BDX)

Public Employees Retirement Association of Colorado boosted its position in Becton Dickinson and Co (NYSE:BDX) by 146.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 548,844 shares of the medical instruments supplier’s stock after purchasing an additional 326,357 shares during the period. Becton Dickinson and accounts for about 0.8% of Public Employees Retirement Association of Colorado’s portfolio, making the stock its 26th biggest holding. Public Employees Retirement Association of Colorado’s holdings in Becton Dickinson and were worth $138,836,000 at the end of the most recent reporting period.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Becton Dickinson and by 0.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock valued at $8,631,529,000 after purchasing an additional 131,536 shares in the last quarter. Vanguard Group Inc. boosted its stake in Becton Dickinson and by 2.3% during the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after buying an additional 520,350 shares during the period. Morgan Stanley lifted its stake in Becton Dickinson and by 66.7% during the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after purchasing an additional 1,955,095 shares during the last quarter. Northern Trust Corp lifted its stake in Becton Dickinson and by 1.5% during the second quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock worth $824,327,000 after purchasing an additional 47,202 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Becton Dickinson and by 4.1% during the second quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock worth $731,162,000 after purchasing an additional 114,398 shares during the last quarter. 84.29% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.08, for a total transaction of $393,761.12. Following the transaction, the senior vice president now owns 5,180 shares in the company, valued at approximately $1,347,214.40. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Alexandre Conroy sold 9,829 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the transaction, the executive vice president now owns 16,535 shares in the company, valued at approximately $4,217,417.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,174 shares of company stock worth $8,354,013. 0.12% of the stock is owned by company insiders.

BDX has been the topic of several analyst reports. Piper Jaffray Companies decreased their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Wells Fargo & Co decreased their price objective on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $266.09.

NYSE:BDX traded up $0.22 during mid-day trading on Friday, reaching $244.79. 1,479,428 shares of the company’s stock traded hands, compared to its average volume of 1,173,922. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $264.74. The firm has a market capitalization of $66.59 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.62 and a beta of 1.09. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.19 and a quick ratio of 0.67. The company has a 50 day moving average price of $251.93 and a 200-day moving average price of $246.89.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company had revenue of $4.58 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the previous year, the business earned $2.93 EPS. Becton Dickinson and’s revenue was up 4.1% compared to the same quarter last year. As a group, analysts forecast that Becton Dickinson and Co will post 12.58 EPS for the current year.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Leave a Reply

Your email address will not be published. Required fields are marked *